Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study

Lenalidomide and low‐dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study

In the FIRST trial (MM‐020), lenalidomide plus low‐dose dexamethasone (Rd) reduced the risk of disease progression or death compared with combination melphalan–prednisone–thalidomide. As the FIRST trial did not include any Japanese patients, the efficacy and safety of continuous treatment with Rd wa...

Full description

Bibliographic Details
Main Authors: Suzuki, Kenshi, Shinagawa, Atsushi, Uchida, Toshiki, Taniwaki, Masafumi, Hirata, Hirokazu, Ishizawa, Kenichi, Matsue, Kosei, Ogawa, Yoshiaki, Shimizu, Takayuki, Otsuka, Maki, Matsumoto, Morio, Iida, Shinsuke, Terui, Yasuhito, Matsumura, Itaru, Ikeda, Takashi, Takezako, Naoki, Ogaki, Yumi, Midorikawa, Shuichi, Houck, Vanessa, Ervin‐Haynes, Annette, Chou, Takaaki
Format: Online
Language:English
Published: John Wiley and Sons Inc. 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970832/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970832/

Similar Items